LMAT LEMAITRE VASCULAR INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1158895 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY11.8%
TTM net income YoY18.7%
TTM EPS YoY18.5%
Revenue 3-yr CAGR13.2%
Net income 3-yr CAGR32.4%
Margins
Gross margin72.0%
Operating margin27.7%
Net margin23.5%
FCF margin24.9%
EBITDA margin31.7%
Returns
ROE15.6%
ROA10.1%
ROIC (approx.)15.3%
Asset turnover0.43x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio14.60x
Interest coverage14.35x
Cash quality & payout
Operating cash flow / net income1.20x
Accruals ratio-2.1%
Payout ratio34.2%
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $249.60M | $219.86M | $193.48M | $161.65M | $154.42M |
| Cost of revenue | $71.06M | $68.96M | $66.44M | $56.76M | $53.04M |
| Gross profit | $178.54M | $150.90M | $127.05M | $104.90M | $101.38M |
| R&D expense | $14.14M | $15.65M | $16.97M | $13.29M | $11.80M |
| SG&A expense | $42.02M | $36.26M | $31.83M | $28.75M | $25.50M |
| Operating income | $67.91M | $52.26M | $36.71M | $26.83M | $36.42M |
| Interest expense | $5.18M | $205,000 | $0 | $0 | $2.22M |
| Pretax income | $75.18M | $56.88M | $39.48M | $27.49M | $34.29M |
| Income tax | $17.45M | $12.84M | $9.37M | $6.85M | $7.38M |
| Net income | $57.73M | $44.04M | $30.11M | $20.64M | $26.91M |
| EBITDA | $78.33M | $61.86M | $46.23M | $36.26M | $47.49M |
| EPS (basic) | 2.55 | 1.96 | 1.36 | 0.94 | 1.27 |
| EPS (diluted) | 2.52 | 1.93 | 1.34 | 0.93 | 1.25 |
| Dividends declared per share | 0.80 | 0.64 | 0.56 | 0.50 | 0.44 |
| Weighted avg. shares (diluted) | 22.93M | 22.78M | 22.42M | 22.17M | 21.48M |
| Balance sheet | |||||
| Cash & equivalents | $28.24M | $25.61M | $24.27M | $19.13M | $13.86M |
| Short-term investments | $330.88M | $274.11M | $80.81M | $63.56M | $56.10M |
| Receivables | $33.61M | $30.06M | $25.06M | $22.04M | $19.63M |
| Current assets | $468.23M | $402.19M | $194.60M | $161.73M | $139.88M |
| PP&E, net | $27.00M | $24.80M | $21.75M | $17.90M | $17.06M |
| Goodwill | $65.94M | $65.94M | $65.94M | $65.94M | $65.94M |
| Intangibles | $33.09M | $35.82M | $41.71M | $46.53M | $52.71M |
| Total assets | $615.69M | $551.82M | $346.78M | $310.48M | $292.80M |
| Current liabilities | $36.32M | $30.61M | $29.88M | $25.33M | $21.81M |
| Total liabilities | $222.17M | $214.53M | $48.88M | $42.27M | $38.65M |
| Shareholders' equity | $393.52M | $337.29M | $297.90M | $268.20M | $254.15M |
| Shares outstanding | 22.77M | 22.55M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | $81.25M | $44.12M | $36.75M | $25.38M | $35.10M |
| Capital expenditure | $6.78M | $6.96M | $7.26M | $3.23M | $4.88M |
| Free cash flow | $74.47M | $37.16M | $29.49M | $22.15M | $30.22M |
| Investing cash flow | -$64.94M | -$200.12M | -$24.71M | -$10.37M | -$61.08M |
| Financing cash flow | -$14.54M | $158.10M | -$7.13M | -$9.23M | $13.70M |
| Depreciation & amortization | $10.42M | $9.61M | $9.52M | $9.43M | $11.07M |
| Stock-based compensation | $7.83M | $6.57M | $5.32M | $4.17M | $3.48M |
| Dividends paid | $18.11M | $14.38M | $12.45M | $10.99M | $9.34M |
| Share buybacks | $1.82M | $1.72M | $853,000 | $642,000 | $802,000 |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.